Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms. The two will work together on an exclusive research basis to advance the study of psilocybin in the treatment of cancer, as well as the discovery of novel uses of undisclosed psychedelic compounds.
Under the collaboration, Revive will have the exclusive right to advance research on the use psilocybin in the treatment of cancer. The partnership will also enable the company to utilize Pharmather’s AI technology, known as panaceAI, to screen, identify, and evaluation psychedelic compounds while focused on pre-specified targets for use with the firms proprietary oral thin film drug delivery technology.
The research jointly conducted will see a focus placed on utilizing Revive’s oral thin film drug delivery technology, which has been optimized for the use of psilocybin and other psychedelics. The company indicated that it will be looking to advance the development of psilocybin in the treatment of numerous types of cancer, including liver carcinoma, melanoma, kidney neoplasms, acute myeloid leukemia, and breast neoplasms.
“We recently achieved an important milestone in expanding our patent portfolio with the potential of psilocybin to treat certain cancer indications. Our research collaboration with Revive validates our business model in discovering novel uses of psychedelics with panaceAI™ and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics.”
Fabio Chianelli, CEO of PharmaTher Inc.
Revive Therapeutics last traded at $0.22 on the CSE.
Sponsored · Cambria Gold Mines
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
